首页> 美国卫生研究院文献>Epidemiology and Psychiatric Sciences >The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports

【2h】

The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports

机译：欧洲药品管理局批准的精神药物证据基础：所有欧洲公共评估报告的荟萃评估

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

To systematically assess the level of evidence for psychotropic drugs approved by the European Medicines Agency (EMA).

机译：系统评估欧洲药品管理局（EMA）批准的精神药物的证据水平。

著录项

期刊名称 Epidemiology and Psychiatric Sciences
作者
Florian Erhel; Alexandre Scanff; Florian Naudet;
展开▼
作者单位

展开▼
年(卷),期 2020(29),-1
年度 2020
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类精神病学;
关键词
Psychopharmacology; psychotropic drugs; randomised controlled trials; research design and methods; systematic reviews;

机译：心理药理学;精神药物;随机对照试验;研究设计和方法;系统评价;

相似文献

外文文献
中文文献
专利

1. The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports [J] . Erhel Florian, Scanff Alexandre, Naudet Florian Epidemiology and psychiatric sciences . 2020,第1期

机译：欧洲药物批准的精神药物批准的证据基础：所有欧洲公共评估报告的META评估
2. Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation? [J] . Marc Maliepaard, Anne C. Taams, Cynthia Sung, Pharmaceutical medicine . 2019,第5期

机译：欧洲药物的特定药物安全数据注册档案档案，欧洲公共评估报告，以及欧洲和新加坡药物标签：丢失翻译？
3. Re: Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009-2013 [J] . Madersbacher Stephan, Kramer Gero European urology . 2018,第4期

机译：Re：欧洲药物批准的癌症药物整体生存和生活质量的益处的效益的可用性：审查队列2009-2013的药物认证研究
4. How Public Transport Could Benefit from Social Media? Evidence from European Agencies [C] . Georgios Georgiadis, Anastasia Nikolaidou, Ioannis Politis, Conference on Sustainable Urban Mobility . 2021

机译：公共交通如何从社交媒体中受益？来自欧洲机构的证据
5. Impact of FDAAA on Registration, Results Reporting, and Publication of Clinical Trials Evaluating New Neuropsychiatric Drugs Approved Between 2005 and 2014 [D] . Zou, Constance Xuanyi. 2019

机译：FDAAA对注册，结果报告和发表临床试验的影响，评估2005年至2014年批准的新神经精神药物
6. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016 [O] . Thomas Christian Kühler, Magda Bujar, Neil McAuslane, 2019

机译：欧洲药品管理局和美国食品药物管理局之间对新活性物质（NAS）的审查结果在多大程度上保持一致？根据2014年至2016年期间最初批准的NAS的公开信息进行比较
7. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency:retrospective cohort study of drug approvals 2009-13 [O] . Davis Courtney, Naci Huseyin, Gurpinar Evrim, 2017

机译：获得欧洲药品管理局批准的关于癌症药物总体生存和生活质量的益处的证据：药物批准的回顾性队列研究2009-13

The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports

摘要

著录项

相似文献

相关主题

期刊订阅